Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 2/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | NCF1 | P14598 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21859736 | 0.86 | CRHR1 (0.38) | CRHR1ARCYP1A2CYP3A4ALOX15 | |
| SCHEMBL21725543 | 0.81 | AR (0.40) | CRHR1ARCYP1A2CYP3A4ALOX15 | |
| SCHEMBL22193256 | 0.80 | AR (0.38) | CRHR1ARCYP1A2CYP3A4ALOX15 | |
| SCHEMBL22193255 | 0.75 | NCF1 (0.38) | CRHR1ARCYP1A2CYP3A4ALOX15 | |
| SCHEMBL21725555 | 0.74 | HPGD (0.36) | MAPK1 | |
| SCHEMBL21725549 | 0.74 | PDE10A (0.39) | CRHR1TSHR | |
| SCHEMBL25332545 | 0.70 | CYP1A2 (0.37) | ARCYP1A2CYP3A4ALOX15TSHR | |
| SCHEMBL30469075 | 0.70 | CYP1A2 (0.37) | ARCYP1A2CYP3A4ALOX15TSHR | |
| SCHEMBL30595652 | 0.70 | NOTUM (0.38) | CRHR1ARCYP1A2CYP3A4ALOX15 | |
| SCHEMBL21725539 | 0.67 | HPGD (0.33) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562884-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562884-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | CRHR1 15/4885AR 413/4885CYP1A2 1383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.